MX2022014364A - Elafibranor para el tratamiento de la colangitis esclerosante primaria. - Google Patents
Elafibranor para el tratamiento de la colangitis esclerosante primaria.Info
- Publication number
- MX2022014364A MX2022014364A MX2022014364A MX2022014364A MX2022014364A MX 2022014364 A MX2022014364 A MX 2022014364A MX 2022014364 A MX2022014364 A MX 2022014364A MX 2022014364 A MX2022014364 A MX 2022014364A MX 2022014364 A MX2022014364 A MX 2022014364A
- Authority
- MX
- Mexico
- Prior art keywords
- elafibranor
- treatment
- sclerosing cholangitis
- primary sclerosing
- cholangitis
- Prior art date
Links
- 206010008609 Cholangitis sclerosing Diseases 0.000 title abstract 2
- 229950001279 elafibranor Drugs 0.000 title abstract 2
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 title abstract 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 title abstract 2
- 208000010157 sclerosing cholangitis Diseases 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Electrotherapy Devices (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a elafibranor o a su metabolito activo, para su uso en un método para el tratamiento de la colangitis esclerosante primaria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305513 | 2020-05-18 | ||
| PCT/EP2021/063075 WO2021233874A1 (en) | 2020-05-18 | 2021-05-18 | Elafibranor for the treatment of primary sclerosing cholangitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014364A true MX2022014364A (es) | 2022-12-15 |
Family
ID=71465234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014364A MX2022014364A (es) | 2020-05-18 | 2021-05-18 | Elafibranor para el tratamiento de la colangitis esclerosante primaria. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230165821A1 (es) |
| EP (1) | EP4153156A1 (es) |
| JP (1) | JP2023526410A (es) |
| KR (1) | KR20230011958A (es) |
| CN (1) | CN115605192A (es) |
| AU (1) | AU2021275381A1 (es) |
| BR (1) | BR112022023368A2 (es) |
| CA (1) | CA3176020A1 (es) |
| IL (1) | IL297436A (es) |
| MX (1) | MX2022014364A (es) |
| TW (1) | TW202207911A (es) |
| WO (1) | WO2021233874A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| KR102856201B1 (ko) | 2023-11-28 | 2025-09-04 | 국립강릉원주대학교산학협력단 | 인공지능 기반으로 기단의 이동경로를 예측하는 방법 및 장치 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| FR2857361B1 (fr) | 2003-07-08 | 2005-09-09 | Genfit S A | PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one |
| FR2902789A1 (fr) | 2006-06-21 | 2007-12-28 | Genfit Sa | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
| IL311687A (en) * | 2016-03-31 | 2024-05-01 | Genfit | Methods for treating gallstone disease |
| FR3056909B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree |
| JP2020533339A (ja) * | 2017-09-13 | 2020-11-19 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む組合せ |
-
2021
- 2021-05-18 MX MX2022014364A patent/MX2022014364A/es unknown
- 2021-05-18 KR KR1020227041124A patent/KR20230011958A/ko active Pending
- 2021-05-18 WO PCT/EP2021/063075 patent/WO2021233874A1/en not_active Ceased
- 2021-05-18 US US17/920,260 patent/US20230165821A1/en active Pending
- 2021-05-18 CA CA3176020A patent/CA3176020A1/en active Pending
- 2021-05-18 CN CN202180033899.5A patent/CN115605192A/zh active Pending
- 2021-05-18 AU AU2021275381A patent/AU2021275381A1/en active Pending
- 2021-05-18 BR BR112022023368A patent/BR112022023368A2/pt unknown
- 2021-05-18 TW TW110117929A patent/TW202207911A/zh unknown
- 2021-05-18 EP EP21725544.7A patent/EP4153156A1/en active Pending
- 2021-05-18 IL IL297436A patent/IL297436A/en unknown
- 2021-05-18 JP JP2022570375A patent/JP2023526410A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4153156A1 (en) | 2023-03-29 |
| WO2021233874A1 (en) | 2021-11-25 |
| US20230165821A1 (en) | 2023-06-01 |
| CA3176020A1 (en) | 2021-11-25 |
| JP2023526410A (ja) | 2023-06-21 |
| TW202207911A (zh) | 2022-03-01 |
| CN115605192A (zh) | 2023-01-13 |
| IL297436A (en) | 2022-12-01 |
| AU2021275381A1 (en) | 2022-11-24 |
| BR112022023368A2 (pt) | 2022-12-20 |
| KR20230011958A (ko) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552497A1 (en) | Enzyme inhibitors | |
| MX2023008193A (es) | Procedimientos para tratar el cáncer. | |
| BR112021020409A2 (pt) | Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase | |
| PH12018500016A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| IL288920A (en) | Glycolate oxidase inhibitors for the treatment of diseases | |
| MY208231A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MY192055A (en) | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| MX2022014364A (es) | Elafibranor para el tratamiento de la colangitis esclerosante primaria. | |
| MX2017002948A (es) | Métodos de tratamiento para la sarcoidosis pulmonar. | |
| MX2023006651A (es) | Tratamiento de la hemofilia con fitusirán. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| BR112018069174A2 (pt) | tratamento de prurido urêmico | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| MX2022011888A (es) | Tratamiento de trastornos respiratorios. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2024009649A (es) | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. | |
| BR112022008639A2 (pt) | Tratamento de distúrbios do fígado | |
| ZA201908087B (en) | Treatment for migraine | |
| MY198500A (en) | Cancer treatment | |
| MX2022013883A (es) | Compuestos de metiltioninio para uso en el tratamiento de covid-19. |